Stryker Co. (NYSE:SYK) Shares Sold by Cohen Capital Management Inc.

Cohen Capital Management Inc. lowered its holdings in shares of Stryker Co. (NYSE:SYK) by 1.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 84,714 shares of the medical technology company’s stock after selling 1,140 shares during the period. Stryker comprises about 5.1% of Cohen Capital Management Inc.’s portfolio, making the stock its 2nd biggest holding. Cohen Capital Management Inc.’s holdings in Stryker were worth $30,501,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Dunhill Financial LLC increased its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker in the 4th quarter worth about $30,000. Darwin Wealth Management LLC acquired a new position in Stryker in the 3rd quarter worth about $36,000. Activest Wealth Management acquired a new position in Stryker in the 4th quarter worth about $36,000. Finally, Crews Bank & Trust acquired a new position in Stryker in the 4th quarter worth about $39,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Stock Down 1.0 %

SYK stock opened at $382.59 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market capitalization of $145.99 billion, a PE ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a 50-day simple moving average of $378.07 and a two-hundred day simple moving average of $368.99.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company earned $3.46 earnings per share. On average, equities analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SYK. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. UBS Group upped their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Truist Financial upped their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Finally, BTIG Research increased their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.